Paperonium

← Back to the plain-language case

Abstract names G3244A where the body names G3242A as the second termination-abolishing pathogenic mutation

Cell (2010) Β· doi:10.1016/j.cell.2010.05.018 Β· PMC2887341

Summary

The Summary (abstract) of this crystal-structure paper on the human mitochondrial transcription terminator MTERF1 ends its results with a disease link: "the mitochondrial pathogenic G3249A and G3244A mutations interfere with key interactions for sequence recognition, eliminating termination." The body of the paper names a different second mutation, G3242A, in each of the three places where it states this result: the Introduction, the Results section on pathogenic mutations, and the Conclusions. The body also describes G3244A in terms that cannot fit the abstract sentence: its base pair makes "no specific interaction" with MTERF1 in the crystal structure, the mutation does not affect DNA binding, and its effect on termination is "moderate". A reader of the abstract alone is therefore told that the wrong variant loses a recognition contact and abolishes termination, and is never told about G3242A, the variant the paper's own data support.

What the paper reports

Abstract (Summary), final results sentence:

Finally, we have demonstrated that the mitochondrial pathogenic G3249A and G3244A mutations interfere with key interactions for sequence recognition, eliminating termination.

Introduction, last paragraph:

We have shown that two mutations, G3249A that causes a variant of Kearns-Sayre syndrome (Seneca et al., 2001) and G3242A that is associated with an uncharacterized mitochondrial disorder (Mimaki et al., 2009), interfere with protein-DNA interactions that are key for sequence recognition by MTERF1 and as a consequence eliminate its transcriptional termination activity.

Results and discussion, "Pathogenic mutations in the leu-tRNA", first paragraph (structure and binding):

All remaining mutations would not be expected to severely conflict with MTERF1 sequence recognition, except for G3242A and G3249A. G3242 interacts in the structure with Arg251, while G3249 forms a double hydrogen bond with Arg387 (Figure 6B). Both of these mutations would eliminate a guanine-arginine interaction: the hydrogen bond between O6 of the guanine and the amino group of the arginine could not be formed in the mutant DNA. Consistent with the mild decrease in binding observed in the R251A mutant, G3242A resulted in weak or no effect on binding. However, the G3249A mutation appears to completely eliminate specific DNA binding (Figure 6A and 3SE), consistent with the effect of the R387A mutation.

Same section, second paragraph (termination assays, Figure 6C/D):

As expected, only residual termination is observed in both orientations with the G3249A mutation. In addition, consistent with what was observed with the R251A mutant, the G3242A mutation, while not substantially altering binding, results nevertheless in a strong decrease in termination.

Unexpectedly, one additional mutation appears to moderately affect termination: G3244A, while not affecting DNA binding, results in a moderate but reproducible effect on termination. Interestingly, no specific interaction is observed in the crystal structure with any of the nucleotides in this base pair. However, it is adjacent to the extrahelical A:T base pair and displays a high base pair buckle (see Experimental Procedures).

Results and discussion, "Conclusions":

An important conclusion derived from the crystal structure is that two pathogenic mutations that interfere with arginine-guanine interactions involved in sequence recognition by MTERF1 result in a strong impairment in the ability of MTERF1 to terminate transcription. G3242A does not substantially affect binding, but very strongly reduces the ability of MTERF1 to terminate transcription, while G3249A appears to completely eliminate specific binding by MTERF1 and consequently severely impairs termination. Their strong effect on termination suggests that the pathogenic effects of the G3249A and G3242A MtDNA mutations might be at least partially mediated by interfering with the activity of MTERF1 at the leu-tRNA site.

Further experiments will be needed to address whether the G3249A and G3242A mutations result in transcriptional alterations in vivo and if this effect is sufficient to explain their clinical phenotype.

What the paper's own numbers show

Method. No arithmetic is involved. The error concerns which mutation is named, so I checked the paper's internal consistency. I parsed the PMC-archived full text and counted every mention of the five leu-tRNA variants the paper discusses (G3242A, A3243G, A3243T, G3244A, G3249A) in each section. I then extracted the pair of mutations that each section names as disrupting sequence recognition and eliminating or strongly impairing termination. Finally, I tabulated what the body says about each candidate's structural contact, its effect on binding and its effect on termination. recompute.py.txt holds the excerpts verbatim, checks all 33 excerpt sentences against the archived text (all found), and prints every value below.

Quantity Location Reported Recomputed from the paper's own text
Second mutation said to disrupt recognition and eliminate termination Abstract (Summary) G3244A (paired with G3249A) Contradicted by all three body sections below
The same pair Introduction, last paragraph G3249A and G3242A G3242A
Mutations expected to conflict with sequence recognition Results, Pathogenic mutations, first paragraph "except for G3242A and G3249A" G3242A
The same pair Conclusions (pair named twice; G3242A mentioned 4 times) G3249A and G3242A G3242A
Agreement of the three body sections with each other Introduction, Results, Conclusions β€” All three name G3249A + G3242A
Agreement of the abstract with the body Abstract vs body β€” No. The pairs differ in one mutation, G3244A vs G3242A, a single-character difference
Mentions of G3242A / G3244A / G3249A Abstract 0 / 1 / 1 G3242A, the body's second mutation, never appears in the abstract
Mentions of G3242A / G3244A / G3249A Introduction 1 / 0 / 1 β€”
Mentions of G3242A / G3244A / G3249A Results, Pathogenic mutations 3 / 2 / 3 G3244A appears only here, as "one additional mutation"
Mentions of G3242A / G3244A / G3249A Conclusions 4 / 0 / 4 β€”
Mentions in the whole article All sections G3242A 8, G3244A 3, G3249A 9 β€”
Structural contact of the mutated base pair Results, Pathogenic mutations G3242 contacts Arg251; G3249 is double hydrogen-bonded to Arg387; G3244 base pair: "no specific interaction is observed" Only G3242A and G3249A can remove a recognition contact
Effect on DNA binding Results, Pathogenic mutations G3242A "weak or no effect"; G3244A "not affecting DNA binding"; G3249A "completely eliminate specific DNA binding" β€”
Effect on termination Results, Pathogenic mutations; Conclusions G3249A "only residual termination"; G3242A "strong decrease" / "very strongly reduces"; G3244A "moderate but reproducible effect" G3244A's effect is moderate, not elimination

By the paper's own account, G3244A meets neither condition in the abstract sentence. It removes no recognition contact, and it does not eliminate termination. G3242A meets the first condition and, in the body's words, comes close to meeting the second ("very strongly reduces").

Figure

The abstract's final results sentence names G3249A and G3244A. The body names G3242A as the second mutation and describes G3244A as making no contact and having a moderate effect.

The top panel holds the abstract's only sentence about the pathogenic mutations, with the second mutation it names (G3244A) in orange. The two lower panels hold verbatim excerpts from the body of the same article. The left panel collects what the Introduction, Results and Conclusions say about G3242A, the mutation they name alongside G3249A: it contacts Arg251, and it strongly decreases termination while leaving binding largely intact. G3242A does not appear in the abstract (dashed connector). The right panel collects everything the body says about G3244A. It appears only in the Results, as "one additional mutation" whose base pair makes no specific contact with MTERF1, which does not affect binding and which has a moderate effect on termination. The solid connector marks the conflict between the abstract's claim about G3244A and the body's description of it. All text is quoted from the PMC-archived article, and the section counts come from recompute.py.txt.

Why it matters

Explanations considered

Status

Suggested correction

  1. In the Summary (abstract), replace "G3249A and G3244A" with "G3249A and G3242A", so that the sentence reads: "Finally, we have demonstrated that the mitochondrial pathogenic G3249A and G3242A mutations interfere with key interactions for sequence recognition, eliminating termination."
  2. Consider aligning the strength of the wording with the Results and Conclusions. G3249A abolishes specific binding and leaves only residual termination, while G3242A barely affects binding but strongly reduces termination. "Severely impairing termination" would match both. The same applies to "eliminate" for G3242A in the Introduction.
  3. Optionally, mention in the abstract that G3244A, which makes no contact with MTERF1, has a moderate effect on termination, because the body presents this as an unexpected finding.
  4. Because the abstract propagates through PubMed and indexing services, a published correction notice linked to the article record would be more effective than a silent change to the online text.